To improve diagnosis and treatment of strokes, Oxygen Biotherapeutics and Aurum Biosciences Ltd of Glasgow, Scotland, will pool their technological resources to conduct preclinical research for imaging and therapeutic intervention of acute ischemic stroke. The research will be conducted by Aurum using Oxygen’s Oxycyte PFC (perfluorocarbon) emulsion in combination with Aurum’s Glasgow Oxygen Level Dependent (GOLD) MRI techniques.

The intent of the research is to better delineate what tissues have been damaged by a stroke, and to determine the effectiveness of the treatment being provided to the model.

According to a letter of intent signed by the companies, Aurum will seek the research funding.

(Source: Press Release)